EAM Investors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

EAM Investors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-30,201	Closed	-$3.24M	–	404
2023 Q1	$3.24M	Sell	30,201 -303	-1%	-$34.9K	0.64%	29
2022 Q4	$3.36M	Sell	30,504 -19,550	-39%	-$1.27M	0.69%	24
2022 Q3	$2.95M	Buy	+50,054	New	+$2.29M	0.64%	31
2022 Q2	–	Sell	-80,587	Closed	-$3.04M	–	385
2022 Q1	$3.04M	Sell	80,587 -2,177	-3%	-$86.1K	0.57%	46
2021 Q4	$3.27M	Buy	+82,764	New	+$2.59M	0.54%	44

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

EAM Investors's RXDX Position: Q2 2023 in Review

EAM Investors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 30,201 shares — an estimated $3.24M sold.

EAM Investors first reported a position in RXDX in Q4 2021 and held it in 5 quarters. The position peaked at $3.36M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

EAM Investors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
EAM Investors sold 30,201 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $3.24M.
EAM Investors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 5 quarters.
EAM Investors's Prometheus Biosciences, Inc. Common Stock position peaked at $3.36M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on EAM Investors's 13F filing for Q2 2023, filed 11 Aug 2023.